Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.42 USD
Change Today -0.015 / -3.45%
Volume 37.8K
ULUR On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

uluru inc (ULUR) Snapshot

Open
$0.44
Previous Close
$0.44
Day High
$0.44
Day Low
$0.35
52 Week High
06/3/14 - $1.60
52 Week Low
04/20/15 - $0.25
Market Cap
10.3M
Average Volume 10 Days
53.2K
EPS TTM
$-0.11
Shares Outstanding
24.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ULURU INC (ULUR)

Related News

No related news articles were found.

uluru inc (ULUR) Related Businessweek News

No Related Businessweek News Found

uluru inc (ULUR) Details

ULURU Inc., a specialty pharmaceutical company, is engaged in the research, development, and commercialization of wound care and mucoadhesive film products in the United States and internationally. The company develops its products based on patented Nanoflex and OraDisc drug delivery technologies. Its products include Altrazeal, a transforming powder dressing for the treatment of various wounds, such as partial thickness burns, donor sites, and abrasions, as well as non-healing surgical, trauma, and chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; Aphthasol for the treatment of canker sores; OraDisc A for the treatment of oral conditions, which rely upon the use of medications formulated as gels and pastes that are applied to lesions in the mouth; and OraDisc B, a mucoadhesive disc product for the treatment and management of oral pain. The company’s OraDisc products are also used for various dental applications. ULURU Inc. is headquartered in Addison, Texas.

7 Employees
Last Reported Date: 04/1/15

uluru inc (ULUR) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $210.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $200.0K
Vice President of Polymer Drug Delivery
Total Annual Compensation: $175.0K
Compensation as of Fiscal Year 2013.

uluru inc (ULUR) Key Developments

ULURU Inc. Announces the Settlement of Outstanding Litigation with Inter-Mountain Capital Corporation

ULURU Inc. announced that they have entered a settlement agreement with Inter-Mountain Capital Corporation to resolve the outstanding litigation associated with a warrant exercise. Under the terms of the settlement, Uluru issued Inter-Mountain 361,516 shares of common stock, issued an unsecured promissory note for $550,000, and a five year warrant to purchase 194,118 shares of common stock at an exercise price of $0.85 per share. Repayment of the promissory note commences 120 days after the issuance of the note, which can be paid in cash or shares of common stock at the company's election. The complaint filed by Inter-Mountain originally claimed 782,234 shares of common stock for the exercise of the warrant and liquidated damages.

ULURU Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Audited Consolidated Earnings Results for the Year Ended December 31, 2014

ULURU Inc. announced unaudited consolidated earnings results for the fourth quarter and audited consolidated earnings results for the year ended December 31, 2014. For the quarter, the company reported total revenues of $229,799 against $129,060 a year ago. Loss before income taxes was $318,028 against income before income taxes of $858,270 a year ago. Net income was $318,028 against net loss of $858,270 a year ago. Net income allocable to common stockholders was $318,028 against net loss allocable to common stockholders of $858,270 a year ago. Basic and diluted net earnings per common share were $0.01 against basic and diluted net loss per common share of $0.04 a year ago. Operating loss was $811,987 against $751,828 a year ago. The increase of approximately $101,000 in revenues from the fourth quarter of 2014 compared to the fourth quarter of 2013 was primarily due to an increase of $99,000 from the sale of Altrazeal to international distributors. For the year, the company reported total revenues of $863,857 against $370,568 a year ago. Loss before income taxes was $1,938,837 against $3,080,914 a year ago. Net loss was $1,938,837 against $3,080,914 a year ago. Net loss allocable to common stockholders was $1,938,837 against $3,111,150 a year ago. Basic and diluted net loss per common share was $0.08 against $0.21 a year ago. Operating loss was $2,904,704 against $2,647,698 a year ago. The increase of approximately $493,000 in Revenue was due principally to an increase of $450,000 in Altrazeal product sales to international distributors and an increase of $33,000 in royalties related to Altrazeal sales by international distributors.

ULURU Inc. announced delayed annual 10-K filing

On 04/01/2015, ULURU Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ULUR:US $0.42 USD -0.015

ULUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $158.99 USD -0.67
Smith & Nephew PLC 1,184 GBp +11.00
View Industry Companies
 

Industry Analysis

ULUR

Industry Average

Valuation ULUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.9x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ULURU INC, please visit www.uluruinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.